Pharmacologic regimens for knee osteoarthritis prevention: can they be cost-effective?

We sought to determine the target populations and drug efficacy, toxicity, cost, and initiation age thresholds under which a pharmacologic regimen for knee osteoarthritis (OA) prevention could be cost-effective